Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lumos Pharma Inc (NQ: LUMO )

2.779 -0.051 (-1.82%)
Streaming Delayed Price Updated: 12:36 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lumos Pharma Inc

< Previous 1 2 Next >
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
From Lumos Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Lumos Pharma Inc. (NASDAQ: LUMO) Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
Webinar to be Held December 6, 2023 at 1:30pm EST 
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3 
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Participation in Investor Conferences in September
From Lumos Pharma, Inc.
Via GlobeNewswire
Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
Virtual Webinar to be held September 5, 2023, at 11:00 AM Eastern Time 
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Departure of Chief Medical Officer
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st
KOL Webinar to be held June 21, 2023 at 11:00 AM Eastern Time 
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Participate in World Orphan Drug Congress USA
From Lumos Pharma, Inc.
Via GlobeNewswire
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
From Lumos Pharma, Inc.
Via GlobeNewswire
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
From Lumos Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.